*Please scroll down to the bottom of the page for the final deliverable.
Storyboard
75 days to a potential cure
From initial inoculation to purified, clinic-ready cGMP therapeutics
How 50 cows are redefining drug discovery and development
What if the drug discovery and development process could be compressed to
Only 75 days from target identification to animal trials?
No antibody screening, straightforward scale-up, and little hands-on time.
This is the vision that the team at SAb Biotherapeutics has already turned into a reality.
And it's all thanks to a small herd of cows that has been engineered to produce fully human antibodies.
The workflow is simple and can be completed in as little as 75 days.
Step 1: Inoculate the cows with the potential drug target, such as viral capsid protein or tumor antigen.
Step 2: Wait for their engineered immune system to start developing antibodies to the target.
Step 3: Harvest plasma.
Step 4: Purify the polyclonal antibodies.
Step 5: Test for potency.
At the end of the 75 days
As many as tens of thousands of doses of cGMP-compliant polyclonal antibodies are ready for
Animal testing, clinical trials, or as approved therapeutic.
Why polyclonal antibodies?
Polyclonal antibodies are an excellent therapeutic choice for indications such as infectious diseases, oncology, autoimmunity, and inflammation.
The power of polyclonal antibodies lies in their broad multi-component activity.
While monoclonal antibodies are chosen for specific, high-affinity binding
Polyclonal preparations consist of a mixture of antibodies that bind to different areas on the antigen at both high and low affinities.
Adding together all the high and low affinity binding in the preparation leads to high potency.
In addition, because polyclonal preparations bind to multiple regions on the antigen
They are able to form an immune complex lattice, which monoclonal antibodies cannot.
This immune complex lattice is more efficiently removed by
Phagocytes, again increasing the potency of polyclonal preparations.
Despite these advantages, the polyclonal antibodies of the past have carried
The risk of adverse effects.
Many are intact antibodies, and their non-human protein sequences can elicit serum sickness and anaphylaxis.
SAb Biotherapeutics engineered cows overcome this problem
By producing fully human antibodies, bringing the power of polyclonal antibodies to life.
Ten cows. 75 days. Tens of thousands of doses of potent, clinic-ready, fully human therapeutic antibody.
With a well-established regulatory path under FDA CBER.
Imagine the possibilities.
Work with SAb Biotherapeutics for more efficient discovery and development.